Fortress Biotech Inc Pref Series A

Fortress Biotech, Inc. is a biopharmaceutical company operating in the United States and internationally. Its commercial products include Emrosi for rosacea, Qbrexza for axillary hyperhidrosis, Accutane for severe recalcitrant nodular acne, Amzeeq for non-nodular moderate to severe acne vulgaris, Zilxi for rosacea lesions, Exelderm antifungal cream, Targadox for severe acne, Luxamend for wounds and burns, and UNLOXCYT for metastatic cutaneous squamous cell carcinoma. The company is also developing CUTX-101 for Menkes disease, IV Tramadol for post-operative acute pain, Dotinurad for gout and chronic kidney diseases, CAEL-101 for amyloid light chain amyloidosis, and Triplex for cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. Formerly known as Coronado Biosciences, Inc., it changed its name to Fortress Biotech, Inc. in April 2015. The company was incorporated in 2006 and is based in Bay Harbor Islands, Florida.